TGTX stock forecast
Our latest prediction for TG Therapeutics, Inc.'s stock price was made on the Jan. 4, 2017 when the stock price was at 4.85$.
In the short term (2weeks), TGTX's stock price should underperform the market by -0.46%. During that period the price should oscillate between -8.41% and +12.89%.
In the medium term (3months), TGTX's stock price should outperform the market by 0.04%. During that period the price should oscillate between -20.52% and +30.79%.Get email alerts
About TG Therapeutics, Inc.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.14$ per share.
The book value per share is 1.22$
Three months stock forecastJan. 4, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|